Leading trade associations in the dietary supplement industry are standing together in opposition to “phenibut,” an illegal ingredient in products fraudulently sold as dietary supplements.
Photo © iStockphoto.com/Zentilia
Leading trade associations in the dietary supplement industry are standing together in opposition to “phenibut,” an illegal ingredient in products fraudulently sold as dietary supplements. Originally developed and used as a drug in the former Soviet Union for supposed brain-enhancing properties, phenibut is not approved as a drug in the United States and has not met regulatory requirements for use as a dietary supplement. Side effects of phenibut can include nausea, poor balance, fatigue, as well as a high risk of dependency when taken regularly, causing withdrawal symptoms following cessation.
The American Herbal Products Association (AHPA), the Consumer Healthcare Products Association (CHPA), the Council for Responsible Nutrition (CRN), and the United Natural Products Alliance (UNPA) have notified FDA about the ingredient, fully supporting the agency’s legal authority to remove phenibut from the marketplace. They have also reached out to several online retailers selling adulterated products containing phenibut to urge them to remove them from inventory. With these actions, the trade associations hope to bring awareness to manufacturers, retailers, and consumers about the dangers of phenibut and demonstrate the industry’s commitment to consumer safety.
Brightseed launches clinically validated ingredient, Bio Gut Core, to support gut barrier function
May 21st 2025The low-dose, easy-to-formulate ingredient is a proprietary blend of two bioactives – N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT) – which were discovered by the company’s Forage AI platform.
A country-by-country blueprint for nutraceutical success in Europe
May 20th 2025The European nutraceutical market is growing rapidly, but the continent is not a monolith when it comes to consumer trends and product innovation. This article is a blue-print for what nutraceutical success looks like in different European countries.